Sun Pharmaceutical Industries Limited Share Price & Analysis

SBI funds $1 billion for Sun Pharma's US acquisition

*SBI funds $1 billion for Sun Pharma's US acquisition*. This funding supports Sun Pharma’s major overseas expansion, marking one of the largest pharma deals by an Indian company. The **$1 billion** infusion underscores strong banking support for strategic acquisitions. Such a significant move could enhance Sun Pharma’s global footprint and revenue potential. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition

SBI may fund $1B for Sun Pharma's $12B Organon buy

*SBI may commit $1 billion to fund Sun Pharma’s $12 billion acquisition of Organon.* This strategic move bolsters Sun Pharma’s global footprint with **$12B** deal size and **$1B** SBI backing. The acquisition could significantly enhance product portfolio and overseas revenue. Regulatory approvals remain pending. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition

Sun Pharma confirms cyber attack, 17TB data breached

*Sun Pharma confirms cyber attack, 17TB data breached.* Hackers accessed **17TB of sensitive data**, disrupting operations and raising concerns over IP security. The company is assessing damage and may face regulatory scrutiny. Clients and partners are being notified of potential data exposure. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #CyberAttack

Sun Pharma eyes $12B Organon acquisition with financing plans

*Sun Pharma eyes $12B Organon acquisition with financing plans* — Sun Pharma is actively evaluating financing options for its proposed $12 billion acquisition of US-based Organon, marking a major strategic expansion. The deal, if completed, would be one of the largest in Indian pharma history. **$12 billion** underscores the scale and global ambition. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition

Sun Pharma to acquire Organon's India business in $12B deal

*Sun Pharma to acquire Organon's India business in $12B deal* — This landmark $12 billion transaction marks one of the largest in India’s pharma sector. The deal will significantly expand Sun Pharma’s portfolio and market reach. It includes Organon’s women’s health and specialty brands. The acquisition is expected to close by 2025 pending regulatory approvals. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Mergers

Dilip Shanghvi leads India's largest pharma acquisition

*Dilip Shanghvi leads India's largest pharma acquisition.* The deal, valued at **₹50,000 crore**, marks a strategic expansion for Sun Pharma. This acquisition strengthens its global footprint and pipeline. It could reshape the domestic pharma landscape. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Pharma

Sun Pharma acquires Organon in $11.75B overseas deal

*Sun Pharma acquires Organon in $11.75B overseas deal* — Sun Pharma has acquired Organon in a landmark deal worth **$11.75 billion**, marking the largest overseas acquisition by an Indian pharma company. The move significantly expands Sun Pharma’s global footprint and generic portfolio. The deal is expected to be accretive to earnings post-integration. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #MergersAndAcquisitions

Sun Pharma makes biggest global acquisition

*Sun Pharma makes biggest global acquisition*. Sun Pharma has announced its largest global acquisition to date, expanding its international footprint. The deal is valued at **$4 billion**, marking a significant move in the global pharma space. This strategic purchase strengthens its specialty portfolio and presence in high-growth markets. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition

Sun Pharma to acquire Organon’s global biosimilars for $11.75B

*Sun Pharma to acquire Organon’s global biosimilars business for $11.75 billion in cash.* This all-cash deal marks one of India’s largest pharma acquisitions, significantly expanding Sun Pharma’s footprint in high-growth biosimilar markets. The acquisition includes **12 commercialized biosimilar products** and a **rich pipeline of 10+ candidates**. The move strengthens India’s global pharma leadership amid rising demand for affordable biologics. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition

Sun Pharma founder comments on $12B Organon acquisition

*Sun Pharma founder comments on $12B Organon acquisition*. He clarified the company is **debt-averse, not risk-averse**, following the landmark deal. The **$12 billion** acquisition marks one of the largest outbound pharma deals by an Indian firm. Strategic expansion into global specialty dermatology is expected to drive long-term growth. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition